Sharp Therapeutics Corp.

C$1.37As of Sun 8 Nov 2026, 12:00 UTC
TSXV:SHRXHealthcare
Country Canada
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (3762.21%)
Biotechnology
Beta (5Y) (1.11)
PE TTM —
TSR TTM (59.94%)
Mkt cap C$43.26M
ROIC (180.75%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.32
(3.89%)
(47.14%)
Sell 0|6|1|12|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
19.40%
20.27%
9.12%
6.81%
Revenue$M
2.077
2.071
2.011
2.109
(1.16%)
(1.89%)
(2.07%)
1.16%
Peers (US$30.62M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.332
—
—
EBIT/Intx
0.881
0.213
0.188
Own earn%
66.74
32.51
63.22
Sh yield%
15.34
40.76
40.48
Owners
Insiders/Inst%
12.25
46.21
Short interest%
3.55
SBC / revenue%
1.08
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
20–26
$1 testx
0.1
Incr. ROIC%
55